CPHI Webinar Series - Pharma Action Against COVID-19 – Listen Now
Listen to recordings of all webinars broadcast during the week of May 04-08
Last week, CPHI ran a series of webinars providing expert insight and analysis on how pharma is responding to the COVID-19 pandemic in several key areas.
The five webinars offered quality content from industry leaders, focusing on important, cutting-edge topics such as the industry’s response to the COVID-19 pandemic, and the impact of the crisis on global supply chains, drug manufacturing, discovery and development.
If you missed any of the webinars, full recordings are available here.
Webinar 1: Response of Pharma to the COVID-19 Pandemic
Date: Monday, May 04, 2020
In our first webinar, we hear views and insights from senior consultants at Informa Pharma Intelligence, Duncan Emerton and Daniel Chancellor, alongside Pfizer CentreOne's Contract Manufacturing Business Leader, Tom Wilson on Pharma's ongoing response to the ongoing coronavirus pandemic.
Webinar 2: Drug Repurposing Trends – a CDMO perspective
Date: Tuesday, May 05, 2020
In this webinar, Anil Kane, Executive Director, Global Head of Technical & Scientific Affairs at Patheon, part of Thermo Fisher Scientific offers a CDMO’s perspective on the latest trends on the low-risk, cost effective drug repurposing strategy to redefine off-patent generics, clinical, shelved drugs or combination drugs to treat different indications and bring them faster to market.
Webinar 3: Managing the Changing Landscape: Building a Flexible, Challenge Resistant and Patient-Centric Clinical Supply Chain
Date: Wednesday, May 06, 2020
During this, the third in our webinar series, we hear from Nicole Gray and Stephen Flaherty, Strategic Supply Solutions at Catalent Pharma Solutions who explore strategies such as alternative supply models to improve supply chain efficiency, reduce risk and respond to local, regional and global challenges during this unprecedented global crisis.
Webinar 4: COVID-19: Impact on Cell and Gene Manufacturing
Date: Thursday, May 07, 2020
The cell and gene sector has exploded in the last few years, offering promising therapies for complex disease profiles for which there was previously no therapeutic solution. In this, the fourth installment of our webinar series, GenScript ProBio and Informa Pharma Intelligence tackle the impact of COVID-19 on the sector and touch on potential cell therapies for the treatment of COVID-19.
Webinar 5: Impact of COVID-19: AI and Machine Learning Solutions
Date: Friday, May 08, 2020
Rounding off our series of webinars, Dr. Yugal Sharma, Senior Director at CAS and Aurelio Arias, Engagement Manager, European Thought Leadership at IQVIA join forces to deliver the analysts’ view on how to optimise artificial intelligence and machine learning for predictive analytics, clinical trials and drug discovery.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance